Lymphedema Diagnostics Market

Lymphedema Diagnostics Market Overview

According to Kings Research, the global lymphedema diagnostics market size was valued at USD 35.1 million in 2024 and is projected to grow from USD 37.2 million in 2025 to USD 59.2 million by 2032, exhibiting a CAGR of 6.88% during the forecast period. 

The growth of the market is fueled by the rising incidence of lymphedema, particularly among cancer patients undergoing lymph node removal or radiation therapy, which necessitates early and accurate diagnosis for effective management. 

Additionally, advancements in non-invasive imaging technologies such as bioimpedance spectroscopy and near-infrared fluorescence imaging are enhancing diagnostic precision and accessibility, supporting broader clinical adoption.

Major companies operating in the lymphedema diagnostics industry are Koninklijke Philips N.V., Siemens Healthineers, Shimadzu Diagnostics Corporation, Solventum, GE HealthCare, FUJIFILM Corporation, Canon Medical Systems Corporation, Quest Medical Imaging B.V., Stryker, KARL STORZ, Hologic, Inc., Mizuho Medical Co., Ltd, Esaote SPA, Hamamatsu Photonics K.K., and Hitachi High-Tech Corporation.

Key Market Highlights:

1. The lymphedema diagnostics market size was valued at USD 35.1 million in 2024.
2. The market is projected to grow at a CAGR of 6.88% from 2025 to 2032.
3. North America held a market share of 37.25% in 2024, with a valuation of USD 13.1 million.
4. The lymphoscintigraphy segment garnered USD 9.9 million in revenue in 2024.
5. The secondary lymphedema segment is expected to reach USD 34.9 million by 2032.
6. The inflammatory diseases segment is anticipated to witness the fastest CAGR of 7.83% over the forecast period.
7. The hospitals segment garnered USD 19.1 million in revenue in 2024.
8. Europe is anticipated to grow at a CAGR of 7.65% through the projection period.

Healthcare providers are increasingly integrating specialized diagnostic tools to improve patient outcomes and streamline lymphedema treatment pathways. This is accelerating adoption across oncology centers, rehabilitation clinics, and specialized lymphedema care units, thereby boosting market growth on a global scale.

• In November 2024, Changi General Hospital in Singapore launched a formal screening programme utilizing Indocyanine Green Lymphography (ICGL) to detect lymphoedema at an early stage. The initiative is designed to enhance timely diagnosis and deliver targeted interventions, ultimately improving patient outcomes and quality of care.

Rising Prevalence of Cancer-Related Lymphedema

The growth of the market is propelled by the increasing prevalence of cancer-related lymphedema, particularly among patients undergoing treatments such as lymph node dissection and radiation therapy. 

As survival rates for cancers like breast, prostate, cervical, and head and neck continue to improve, more individuals are living with the long-term side effects of treatment, including secondary lymphedema. 

According to the American Cancer Society, breast cancer surgeries that involve lymph node removal, typically 2 to 3 nodes in a sentinel lymph node biopsy and up to 30 nodes in an axillary lymph node dissection, significantly increase the risk of developing lymphedema.  The risk increases with the number of nodes removed, highlighting the need for early diagnosis.

This rise in cases is creating a pressing need for early and reliable diagnostic methods that enable timely intervention and reduce the risk of irreversible tissue damage. The demand is further supported by the integration of lymphedema screening in survivorship care plans and the growing recognition of the importance of long-term quality of life in cancer recovery. 

As healthcare providers focus on comprehensive post-treatment management, investment in advanced lymphedema diagnostics is accelerating, thereby driving market growth.

High Costs of Advanced Diagnostics

High costs associated with advanced diagnostics pose a significant challenge in the lymphedema diagnostics market, particularly in resource-limited settings. Technologies such as bioimpedance spectroscopy, near-infrared fluorescence imaging, and lymphoscintigraphy require expensive equipment, trained personnel, and ongoing maintenance, making them inaccessible for many smaller clinics and healthcare facilities. 

Moreover, limited insurance coverage and inadequate reimbursement policies further increase the issue, especially in developing economies where healthcare budgets are constrained.

To overcome these challenges, market players are developing more cost-effective diagnostic solutions and portable devices that can be integrated into primary care settings. Key players are also expanding reimbursement support, offering tiered product pricing, and providing training programs to enable broader clinical adoption and equitable access across healthcare systems.

Advancements in Non-Invasive Imaging Technologies

Advancements in non-invasive imaging technologies are significantly transforming the market by enabling safer, more accurate, and patient-centric diagnostic procedures. 

These technologies allow real-time visualization of lymphatic structures and fluid dynamics without the risks associated with invasive methods or radiation exposure, improving both diagnostic confidence and patient comfort. Innovations in high-resolution imaging modalities are enhancing the early detection and staging of lymphedema, supporting timely and targeted intervention. 

They also offer improved reproducibility and standardization in clinical assessments, which is essential for consistent patient monitoring and outcome measurement.

Additionally, the development of compact and portable imaging systems is expanding access to diagnostic services across outpatient clinics, rehabilitation centers, and underserved regions. 

As healthcare systems increasingly prioritize early intervention and chronic disease management, non-invasive imaging technologies are playing a crucial role in modernizing lymphedema diagnosis and advancing market expansion. 

• In September 2024, the National Center for Biotechnology Information (NCBI) published a comprehensive review evaluating various diagnostic methods for lymphedema. The report covered both conventional approaches, such as limb circumference assessments, and advanced imaging modalities like MRI and Indocyanine Green (ICG) lymphography. It highlighted the need for selecting diagnostic tools based on individual clinical contexts and introduced a practical framework to guide personalized and effective diagnostic strategies in lymphedema management.

Lymphedema Diagnostics Market Report Snapshot

Market Segmentation

• By Technology (Lymphoscintigraphy, Near-Infrared Fluorescence Imaging, Bioimpedance Analysis, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and X-Ray Lymphography): The lymphoscintigraphy segment earned USD 9.9 million in 2024 due to its widespread use as a gold-standard technique for visualizing lymphatic function and diagnosing lymphedema.
• By Disease Type (Secondary Lymphedema, and Primary Lymphedema): The secondary lymphedema segment held a share of 63.91% in 2024, attributed to its higher prevalence driven by cancer treatments, surgeries, infections, and trauma that disrupts normal lymphatic flow.
• By Application (Cancer-related Lymphedema, Cardiovascular Diseases, Inflammatory Diseases, and Others): The cancer-related lymphedema segment is projected to reach USD 28.4 million by 2032, owing to the increasing incidence of cancer treatments such as lymph node dissection and radiation therapy that elevate the risk of lymphatic complications.
• By End User (Hospitals, Diagnostic Centers, Research & Academic Institutes, and Others): The diagnostic centers segment is anticipated to grow at a CAGR of 7.60% through the projection period attributed to the growing demand for early-stage lymphedema detection and the increasing adoption of advanced diagnostic technologies in specialized outpatient settings.

Lymphedema Diagnostics Market Regional Analysis

Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

North America lymphedema diagnostics market share stood at 37.25% in 2024, valued at USD 13.1 million. This dominance is attributed to a well-established healthcare infrastructure, high awareness of lymphatic disorders, and strong adoption of advanced diagnostic technologies supported by favorable reimbursement policies. 

Additionally, the presence of key market players and ongoing clinical research initiatives are boosting regional market growth. Increasing cancer survivorship and proactive screening practices are driving demand for accurate lymphedema diagnostics across hospitals and outpatient settings. 

Furthermore, rising healthcare expenditure and the integration of non-invasive imaging tools in routine care are expanding diagnostic capabilities and accelerating market penetration across North America.

• In April 2024, The Advanced Research Projects Agency for Health (ARPA-H) an agency within the U.S. Department of Health and Human Services (HHS), launched the LIGHT program to advance diagnostics for lymphatic disorders, including lymphedema. The initiative focuses on developing innovative tools such as imaging technologies, biomarkers, and genetic profiling to enable early detection and personalized care, marking a significant boost to the market.

The Europe lymphedema diagnostics industry is set to grow at a CAGR of 7.65% over the forecast period. This growth is attributed to rising awareness of lymphatic health, increasing incidence of chronic diseases, and growing demand for early diagnostic solutions across the region. 

The presence of a well-structured public healthcare system, coupled with expanding access to specialized diagnostic services, supports the adoption of advanced imaging technologies for lymphedema detection. Government-led initiatives promoting early intervention and chronic disease management are further driving the market. 

Additionally, increasing collaborations between healthcare providers, research institutes, and diagnostic technology developers are enhancing diagnostic accuracy and availability, thereby accelerating regional market growth.

Regulatory Frameworks

• In the U.S., 21 CFR Part 892 – Radiology Devices regulates diagnostic imaging systems used in lymphedema diagnostics. It outlines classification requirements and performance standards for technologies such as MRI, X-ray angiographic systems, and gamma cameras, ensuring these devices are safe and effective for visualizing lymphatic structures and supporting accurate clinical diagnosis.
• In the European Union, Regulation (EU) 2017/745 – Medical Devices Regulation (MDR) governs diagnostic tools used in lymphedema assessment. It sets strict standards for safety, clinical evaluation, and performance, ensuring imaging and measurement devices are effective and reliable for diagnosing lymphatic conditions.
• In Canada, the Medical Devices Regulations (SOR/98-282) regulates medical devices used in lymphedema diagnostics. They establish requirements for device classification, licensing, safety, and effectiveness, ensuring that diagnostic tools such as imaging and measurement systems meet stringent standards before clinical use.
• In India, the Medical Devices Rules, 2017 regulate diagnostic medical devices used in lymphedema assessment. They outline a risk-based classification system and set requirements for safety, performance, and licensing to ensure that such devices meet quality standards before being marketed or used in clinical settings.
• Globally, ISO 13485:2016 – Medical Devices – Quality Management Systems governs the design and manufacture of diagnostic devices used in lymphedema. It defines requirements for establishing effective quality management systems across design, production, and servicing, ensuring these tools consistently meet standards for safety, performance, and regulatory compliance.

Competitive Landscape

The lymphedema diagnostics market comprises a mix of leading medical imaging companies and niche diagnostic specialists, all working to expand their market footprint through innovation, advanced technologies, and strategic collaborations. 

Companies are investing significantly in research and development to enhance diagnostic accuracy, improve patient comfort, and integrate advanced imaging technologies such as near-infrared fluorescence, bioimpedance analysis, and high-resolution MRI. 

Additionally, companies are also expanding their portfolios to include portable and non-invasive diagnostic systems to meet the growing demand for outpatient and home-based care. 

Furthermore, strategic collaborations with hospitals, research institutions, and oncology centers are being pursued to improve clinical validation, broaden application reach, and accelerate product adoption across global healthcare markets.

• In February 2025, ImpediMed secured USD 15 million in funding from SWK Holdings to advance the commercialization of its FDA-cleared SOZO Digital Health Platform for early detection of breast cancer–related lymphedema. The investment aims to expand access to non-invasive diagnostics and enhance patient care. 

Key Companies in Lymphedema Diagnostics Market:

• Koninklijke Philips N.V.
• Siemens Healthineers
• Shimadzu Diagnostics Corporation
• Solventum
• GE HealthCare
• FUJIFILM Corporation
• Canon Medical Systems Corporation
• Quest Medical Imaging B.V.
• Stryker
• KARL STORZ
• Hologic, Inc.
• Mizuho Medical Co., Ltd
• Esaote SPA
• Hamamatsu Photonics K.K.
• Hitachi High-Tech Corporation

Recent Developments (Expansion)

• In February 2025, Healthpoint, part of the M42 Group, Abu Dhabi, expanded its plastic and reconstructive surgery services to include multidisciplinary care for lipedema and lymphedema. The new clinic incorporates advanced AI-driven technology for lymph vessel mapping, node visualization, and lymph flow assessment, enabling comprehensive diagnostics and personalized treatment plans across conservative and surgical approaches.